乳腺癌患者外周血T淋巴细胞AgNOR活性表达及其临床意义

The Expression of AgNOR in Peripheral Blood T Lymphocyte in Patients with Breast Cancer and Its Clinical Significance

目的:探讨乳腺癌患者外周血T淋巴细胞AgNOR的活性表达及其与临床病理因素的相关性。方法:利用KL型图像分析系统检测80例乳腺癌患者,40例乳腺纤维腺瘤患者,25例乳腺炎症患者和75例健康人外周血T淋巴细胞AgNOR的活性表达(T淋巴细胞核仁银染面积与细胞核面积比值,即I.S%),并与乳腺癌患者临床病理因素进行相关性分析。双抗体夹心法检测乳腺癌患者CA153和CEA。结果:发现乳腺癌患者外周血T淋巴细胞AgNOR的活性表达(5.88±6.05%)明显低于健康人(7.07±0.81%)、乳腺纤维腺瘤患者(6.58±0.72%)和乳腺炎症患者(9.58±0.68%)(P=0.000);乳腺炎症患者AgNOR的活性表达明显高于健康人、乳腺纤维腺瘤和乳腺癌患者(P=0.000);健康人与乳腺纤维腺瘤患者之间比较无显著性差异(P>0.05)。乳腺癌患者AgNOR阳性率(65.00%)明显优于CA153(17.50%)和CEA(12.50%)的阳性率(P=0.000)。AgNOR表达与乳腺癌临床分期有关(P<0.05),而与年龄、肿瘤大小、淋巴结转移状况无相关性(P>0.05)。结论:AgNOR阳性表达可作为评价乳腺癌发生、发展的客观生物学指标;在乳腺癌诊断、鉴别诊断和病情监测等方面有重要意义。

Objective： To investigate the expression of AgNOR in peripheral blood T lymphocyte of breast cancer, and their correlation with clinical pathological significance. Methods： The expression of AgNOR in peripheral blood T lymphocyte in 80 patients with breast Cancer, 40 patients with breast fibroadenoma, 25 Patents with mastitis and 75 patents with healthy controls by the KL imaging system （the ratio of silver stained nucleolus area and nucleolus area of T lymphocyte, LS%）, and their correlation with clinical pathological factors was explored. At the same time, CA153 and carcinoembryonic antigen （CEA） were measured by bio-antibody sandwich. Results： The expression of AgNOR in peripheral blood T lymphocyte in patients with breast cancer （5.88±6.05%） was much lower than that of the healthy control group （7.07±0.81%）, breast fibroadenoma （6.58±0.72%） and mastitis （9.58±0.68%） （P= 0.000）. The expression of AgNOR in patients with mastitis was much higher compared to the healthy control group, breast fibroadenoma and breast Cancer （P=0.000）; There was no statistical difference between the subjects with healthy control group and breast fibroadenoma（P〉0.05）. The positive rate of AgNOR （65.00%） was much higher than that CA153 （17.50%）and CEA （12.50%）in patients with breast Cancer （P=0.000）. The expression of AgNOR was positively correlated with tumor stages （P〈0.05）, but was not related to age, tumor size, lymph node status （P〉0.05）. Conclusion： The expression of AgNOR is a objective biological parameter to estimate the development and progression of breast cancer. In addition, the results demonstrated that the analysis of AgNOR might play an important role in the diagnosis, differenciation and clinical monitoring or cancers.